Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Financial Ratios
1 years of historical data (2024–2024) · Financial Services · Shell Companies
EV/EBITDA
9999.00
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
N/A
—
5yr avg: N/A
Debt/EBITDA
902.35
+0% vs avg
5yr avg: 902.35
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DMAA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Drugs Made In America Acquisition Corp. Ordinary Shares currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 |
|---|---|---|
| Market Cap | $111M | — |
| Enterprise Value | $111M | — |
| P/E Ratio → | -189.29 | — |
| P/S Ratio | — | — |
| P/B Ratio | — | — |
| P/FCF | — | — |
| P/OCF | — | — |
P/E links to full P/E history page with 30-year chart
DMAA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Drugs Made In America Acquisition Corp. Ordinary Shares's enterprise value stands at 9999.0x EBITDA. The Financial Services sector median is 11.4x, placing the stock at a 87542% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 |
|---|---|---|
| EV / Revenue | — | — |
| EV / EBITDA | 9999.00 | — |
| EV / EBIT | — | — |
| EV / FCF | — | — |
DMAA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 |
|---|---|---|
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Profit Margin | — | — |
Return on Capital
| Metric | TTM | FY 2024 |
|---|---|---|
| ROE | — | — |
| ROA | -87.0% | -87.0% |
| ROIC | — | — |
| ROCE | — | — |
DMAA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Drugs Made In America Acquisition Corp. Ordinary Shares carries a Debt/EBITDA ratio of 902.3x, which is highly leveraged (21672% above the sector average of 4.1x). Net debt stands at $661 ($662 total debt minus $1351 cash).
| Metric | TTM | FY 2024 |
|---|---|---|
| Debt / Equity | — | — |
| Debt / EBITDA | 902.35 | 902.35 |
| Net Debt / Equity | — | — |
| Net Debt / EBITDA | 900.51 | 661.00 |
| Debt / FCF | — | — |
| Interest Coverage | — | — |
DMAA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Drugs Made In America Acquisition Corp. Ordinary Shares's current ratio of 6.27x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities.
| Metric | TTM | FY 2024 |
|---|---|---|
| Current Ratio | 6.27 | 6.27 |
| Quick Ratio | 6.27 | 6.27 |
| Cash Ratio | 1.70 | 1.70 |
| Asset Turnover | — | — |
| Inventory Turnover | — | — |
| Days Sales Outstanding | — | — |
DMAA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Drugs Made In America Acquisition Corp. Ordinary Shares does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 |
|---|---|---|
| Dividend Yield | — | — |
| Payout Ratio | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 |
|---|---|---|
| Earnings Yield | — | — |
| FCF Yield | — | — |
| Buyback Yield | 0.0% | — |
| Total Shareholder Yield | 0.0% | — |
| Shares Outstanding | — | $9M |
Peer Comparison
Compare DMAA with 9 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DMAAYou | $111M | -189.3 | 9999.0 | — | — | — | — | — | 902.3 |
 HCAI | $13M | 8.0 | 8.0 | 8.6 | 14.0% | 5.5% | 5.5% | 4.2% | 3.8 |
 BRTX | $2M | -0.2 | — | — | 93.0% | -2881.6% | -96.9% | -100.4% | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 MRK | $275B | 15.3 | 10.6 | 22.3 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $146B | 18.9 | 10.4 | 16.1 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 ABBV | $356B | 85.0 | 14.9 | 20.0 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 BMY | $115B | 16.3 | 9.2 | 8.9 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 LLY | $896B | 41.3 | 29.8 | 99.9 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 AMGN | $179B | 23.3 | 14.2 | 22.1 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
| Financial Services Median | — | 13.3 | 11.4 | 10.6 | 63.4% | 21.5% | 9.4% | 5.7% | 4.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 1 years · Updated daily
See DMAA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DMAA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DMAA vs HCAI
Side-by-side business, growth, and profitability comparison vs Hauchen AI Parking Management Technology Holding Co., Ltd..
Start ComparisonDMAA — Frequently Asked Questions
Quick answers to the most common questions about buying DMAA stock.
What is Drugs Made In America Acquisition Corp. Ordinary Shares's P/E ratio?
Drugs Made In America Acquisition Corp. Ordinary Shares's current P/E ratio is -189.3x. This places it at the 50th percentile of its historical range.
What is Drugs Made In America Acquisition Corp. Ordinary Shares's EV/EBITDA?
Drugs Made In America Acquisition Corp. Ordinary Shares's current EV/EBITDA is 9999.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Is DMAA stock overvalued?
Based on historical data, Drugs Made In America Acquisition Corp. Ordinary Shares is trading at a P/E of -189.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
How much debt does Drugs Made In America Acquisition Corp. Ordinary Shares have?
Drugs Made In America Acquisition Corp. Ordinary Shares's Debt/EBITDA ratio is 902.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.